Japan’s PMDA releases guidance on evaluating generative AI-enabled medical devices

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has published a set of review points aimed at medical devices that incorporate generative artificial intelligence. The guidance outlines the principles regulators will use to assess these technologies, focusing on safety, performance and data integrity.

The document provides a framework for developers to demonstrate that AI‑driven devices meet established standards for clinical effectiveness and risk management. It also highlights the importance of transparent algorithms and robust validation studies.

By issuing these review points, the PMDA signals a proactive approach to integrating emerging AI tools into Japan’s medical‑device regulatory landscape, offering clearer expectations for manufacturers and potentially shaping industry practices across the region.